Bangladesh · Delayed Price · Currency is BDT DSE:BXPHARMA Statistics
Total Valuation
DSE:BXPHARMA has a market cap or net worth of BDT 66.02 billion. The enterprise value is 67.45 billion.
| Market Cap | 66.02B |
| Enterprise Value | 67.45B |
Important Dates
The next estimated earnings date is Tuesday, November 3, 2026.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | Aug 3, 2026 |
Share Statistics
DSE:BXPHARMA has 446.11 million shares outstanding.
| Current Share Class | 446.11M |
| Shares Outstanding | 446.11M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.10% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 7.63 and the forward PE ratio is 7.62.
| PE Ratio | 7.63 |
| Forward PE | 7.62 |
| PS Ratio | 1.22 |
| PB Ratio | 1.03 |
| P/TBV Ratio | 1.21 |
| P/FCF Ratio | 9.12 |
| P/OCF Ratio | 6.31 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.11, with an EV/FCF ratio of 9.31.
| EV / Earnings | 7.80 |
| EV / Sales | 1.25 |
| EV / EBITDA | 5.11 |
| EV / EBIT | 5.95 |
| EV / FCF | 9.31 |
Financial Position
The company has a current ratio of 4.13, with a Debt / Equity ratio of 0.05.
| Current Ratio | 4.13 |
| Quick Ratio | 1.40 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.24 |
| Debt / FCF | 0.44 |
| Interest Coverage | 16.64 |
Financial Efficiency
Return on equity (ROE) is 14.71% and return on invested capital (ROIC) is 14.31%.
| Return on Equity (ROE) | 14.71% |
| Return on Assets (ROA) | 9.22% |
| Return on Invested Capital (ROIC) | 14.31% |
| Return on Capital Employed (ROCE) | 15.75% |
| Weighted Average Cost of Capital (WACC) | 6.14% |
| Revenue Per Employee | 44.09M |
| Profits Per Employee | 7.07M |
| Employee Count | 1,223 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 1.86 |
Taxes
In the past 12 months, DSE:BXPHARMA has paid 2.53 billion in taxes.
| Income Tax | 2.53B |
| Effective Tax Rate | 22.36% |
Stock Price Statistics
The stock price has increased by +43.55% in the last 52 weeks. The beta is 0.25, so DSE:BXPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | +43.55% |
| 50-Day Moving Average | 136.32 |
| 200-Day Moving Average | 119.35 |
| Relative Strength Index (RSI) | 53.79 |
| Average Volume (20 Days) | 1,586,823 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DSE:BXPHARMA had revenue of BDT 53.93 billion and earned 8.65 billion in profits. Earnings per share was 19.39.
| Revenue | 53.93B |
| Gross Profit | 25.57B |
| Operating Income | 11.33B |
| Pretax Income | 11.32B |
| Net Income | 8.65B |
| EBITDA | 13.11B |
| EBIT | 11.33B |
| Earnings Per Share (EPS) | 19.39 |
Balance Sheet
The company has 5.78 billion in cash and 3.16 billion in debt, with a net cash position of 2.62 billion or 5.87 per share.
| Cash & Cash Equivalents | 5.78B |
| Total Debt | 3.16B |
| Net Cash | 2.62B |
| Net Cash Per Share | 5.87 |
| Equity (Book Value) | 64.10B |
| Book Value Per Share | 134.60 |
| Working Capital | 21.26B |
Cash Flow
In the last 12 months, operating cash flow was 10.47 billion and capital expenditures -3.23 billion, giving a free cash flow of 7.24 billion.
| Operating Cash Flow | 10.47B |
| Capital Expenditures | -3.23B |
| Depreciation & Amortization | 1.78B |
| Net Borrowing | -4.33B |
| Free Cash Flow | 7.24B |
| FCF Per Share | 16.23 |
Margins
Gross margin is 47.42%, with operating and profit margins of 21.01% and 16.04%.
| Gross Margin | 47.42% |
| Operating Margin | 21.01% |
| Pretax Margin | 20.99% |
| Profit Margin | 16.04% |
| EBITDA Margin | 24.31% |
| EBIT Margin | 21.01% |
| FCF Margin | 13.43% |
Dividends & Yields
This stock pays an annual dividend of 4.75, which amounts to a dividend yield of 3.21%.
| Dividend Per Share | 4.75 |
| Dividend Yield | 3.21% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 2.45% |
| Buyback Yield | n/a |
| Shareholder Yield | 3.21% |
| Earnings Yield | 13.10% |
| FCF Yield | 10.97% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for DSE:BXPHARMA is 145.75, which is -1.52% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | 145.75 |
| Price Target Difference | -1.52% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 10.81% |
| EPS Growth Forecast (3Y) | 14.24% |
Stock Splits
The last stock split was on November 26, 2020. It was a forward split with a ratio of 1.1.
| Last Split Date | Nov 26, 2020 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
DSE:BXPHARMA has an Altman Z-Score of 4.3 and a Piotroski F-Score of 8.
| Altman Z-Score | 4.3 |
| Piotroski F-Score | 8 |